Medtronic SPR Therapeutics acquisition expands neuromodulation portfolio with $650M deal adding temporary peripheral nerve stimulation technology to strengthen early chronic pain intervention and non-opioid minimally invasive treatment options.
|
Medtronic’s SPR Therapeutics acquisition represents the strategic move made by Medtronic plc in order to increase its offering of neuromodulation products. In acquiring SPR Therapeutics, one of the leading companies developing temporary PNS devices, Medtronic is targeting the provision of innovative, minimally invasive treatments that do not contain opioid components. The acquisition responds to the rising demand for the development of less risky, early and advanced approaches in managing chronic pain within the health care systems of various nations.
Expanding Temporary Peripheral Nerve Stimulation for Chronic Pain
This transaction involves the integration of the FDA approved SPRINT® system of Sprout Therapeutics. The SPRINT® device is a 60 day device that provides targeted peripheral nerve stimulation that does not require any permanent implantation. Through the application of this system, doctors will be able to provide intervention earlier in the treatment process since they will be using a technique that is minimally invasive. Using this system, doctors will be able to stimulate selected peripheral nerves in order to reduce pain and enhance functionality for the duration of the treatment process.
Strengthening Non-Opioid Pain Management Solutions
With rising issues regarding opioid usage and dependence on medication, Medtronic is putting a strong emphasis on its products for managing pain without resorting to opioids. With the addition of the technologies of SPR, Medtronic is moving towards promoting the usage of neuromodulation techniques that reduce drug dependence, along with better treatment results. Based on clinical studies on the efficacy of the SPRINT® system, Medtronic will be able to deliver significant levels of pain reduction along with a better quality of life. Business Honor views this acquisition as a meaningful step toward advancing safer, earlier, and more patient-centric chronic pain care solutions.
.webp)
